Article: FDA backs Vytorin after finishing study review

The Food and Drug Administration said Thursday patients should not stop taking Vytorin or other cholesterol-lowering drugs, based on its just-completed review of a controversial study that hammered Vytorin sales.

A statement from the regulatory agency said it is sticking to its original position that medicines that reduce bad cholesterol benefit patients at risk of heart attack, stroke, or sudden death.

"What the FDA is saying is exactly the way I'm practicing," said former American Heart Association President Dr. Valentin Fuster, now director of the Mount Sinai Heart Center in New York.

Dr. Timothy Gardner, the current heart association president, said he ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!